Innate Pharma receives PRIME designation from the European Medicines Agency for lacutamab in Sézary syndrome
Innate Pharma to participate in upcoming investor conferences
Innate Pharma launches HopeConnectLearn: a new online resource for hairy cell leukemia patients
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Number of shares and voting rights of Innate Pharma as of October 1, 2020
Innate Pharma reports first half 2020 financial results and business update
Upcoming investor conferences
Number of shares and voting rights of Innate Pharma as at August 1, 2020
Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature
